Terms: = Breast cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Treatment
169 results:
1. Neratinib for HER2-positive breast cancer with an overlooked option.
Guo L; Shao W; Zhou C; Yang H; Yang L; Cai Q; Wang J; Shi Y; Huang L; Zhang J
Mol Med; 2023 Oct; 29(1):134. PubMed ID: 37803271
[TBL] [Abstract] [Full Text] [Related]
2. Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy.
Chaudhary LN; Jorns JM; Sun Y; Cheng YC; Kamaraju S; Burfeind J; Gonyo MB; Kong AL; Patten C; Yen T; Cortina CS; Carson E; Johnson N; Bergom C; Tsaih SW; Banerjee A; Wang Y; Chervoneva I; Weil E; Chitambar CR; Rui H
Breast Cancer Res Treat; 2023 Oct; 201(3):387-396. PubMed ID: 37460683
[TBL] [Abstract] [Full Text] [Related]
3. Vitamin D analog calcitriol for breast cancer therapy; an integrated drug discovery approach.
B S N; P K KN; Akey KS; Sankaran S; Raman RK; Natarajan J; Selvaraj J
J Biomol Struct Dyn; 2023 Dec; 41(20):11017-11043. PubMed ID: 37054526
[TBL] [Abstract] [Full Text] [Related]
4. Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines.
Tawfeeq N; Lazarte JMS; Jin Y; Gregory MD; Lamango NS
Oncotarget; 2023 Mar; 14():243-257. PubMed ID: 36961909
[TBL] [Abstract] [Full Text] [Related]
5. Deciphering the Role and Signaling Pathways of PKCα in Luminal A breast cancer Cells.
Serrano-López EM; Coronado-Parra T; Marín-Vicente C; Szallasi Z; Gómez-Abellán V; López-Andreo MJ; Gragera M; Gómez-Fernández JC; López-Nicolás R; Corbalán-García S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430510
[TBL] [Abstract] [Full Text] [Related]
6. Life after Cleavage: The Story of a β-Retroviral (MMTV) Signal Peptide-From Murine Lymphoma to Human breast cancer.
Hochman J; Braitbard O
Viruses; 2022 Nov; 14(11):. PubMed ID: 36366533
[TBL] [Abstract] [Full Text] [Related]
7. Etoposide-induced MicroRNA-205-5p Suppresses Proliferation and Migration by Targeting erbb4 in MCF-7 Cells.
Son SW; Heo SH; Oh SS; Lee CH; Park JK
Anticancer Res; 2022 Sep; 42(9):4265-4272. PubMed ID: 36039421
[TBL] [Abstract] [Full Text] [Related]
8. Beyond HER2: Targeting the ErbB receptor family in breast cancer.
Drago JZ; Ferraro E; Abuhadra N; Modi S
Cancer Treat Rev; 2022 Sep; 109():102436. PubMed ID: 35870237
[TBL] [Abstract] [Full Text] [Related]
9. A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.
Salawu A; Hansen AR; Spreafico A; Al-Ezzi E; Webster S; Bedard PL; Doi J; Wang L; Siu LL; Abdul Razak AR
Target Oncol; 2022 May; 17(3):271-281. PubMed ID: 35635640
[TBL] [Abstract] [Full Text] [Related]
10. The HER family as therapeutic targets in colorectal cancer.
Ye P; Wang Y; Li R; Chen W; Wan L; Cai P
Crit Rev Oncol Hematol; 2022 Jun; 174():103681. PubMed ID: 35462030
[TBL] [Abstract] [Full Text] [Related]
11. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the treatment of cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
12. Diagnosis and treatment of ERBB2-Positive Metastatic Colorectal cancer: A Review.
Strickler JH; Yoshino T; Graham RP; Siena S; Bekaii-Saab T
JAMA Oncol; 2022 May; 8(5):760-769. PubMed ID: 35238866
[TBL] [Abstract] [Full Text] [Related]
13. Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors.
Lee MX; Wong ALA; Ow S; Sundar R; Tan DSP; Soo RA; Chee CE; Lim JSJ; Yong WP; Lim SE; Goh BC; Wang L; Lee SC
Target Oncol; 2022 Mar; 17(2):141-151. PubMed ID: 35195837
[TBL] [Abstract] [Full Text] [Related]
14. The efficacy of pyrotinib-based therapy in lapatinib-resistant metastatic HER2-positive breast cancer.
Yang C; Shangguan C; Lou G; Qu Q
Ann Palliat Med; 2022 Jan; 11(1):332-338. PubMed ID: 35144424
[TBL] [Abstract] [Full Text] [Related]
15. The Yin and Yang of erbb4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
16. erbb4-mediated regulation of vasculogenic mimicry capability in breast cancer cells.
Kawahara R; Simizu S
Cancer Sci; 2022 Mar; 113(3):950-959. PubMed ID: 34971015
[TBL] [Abstract] [Full Text] [Related]
17. Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
Tesch ME; Speers C; Diocee RM; Gondara L; Peacock SJ; Nichol A; Lohrisch CA
Cancer; 2022 Feb; 128(4):665-674. PubMed ID: 34855202
[TBL] [Abstract] [Full Text] [Related]
18. Anti‑HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma.
Asano T; Ohishi T; Takei J; Nakamura T; Nanamiya R; Hosono H; Tanaka T; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184091
[TBL] [Abstract] [Full Text] [Related]
19. Development and Validation of a breast cancer Risk Prediction Model for Childhood cancer Survivors Treated With Chest Radiation: A Report From the Childhood cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts.
Moskowitz CS; Ronckers CM; Chou JF; Smith SA; Friedman DN; Barnea D; Kok JL; de Vries S; Wolden SL; Henderson TO; van der Pal HJH; Kremer LCM; Neglia JP; Turcotte LM; Howell RM; Arnold MA; Schaapveld M; Aleman B; Janus C; Versluys B; Leisenring W; Sklar CA; Begg CB; Pike MC; Armstrong GT; Robison LL; van Leeuwen FE; Oeffinger KC
J Clin Oncol; 2021 Sep; 39(27):3012-3021. PubMed ID: 34048292
[TBL] [Abstract] [Full Text] [Related]
20. [Application of neratinib in the treatment of hormone receptor and HER-2 double positive breast cancer].
Wang X; Yuan P
Zhonghua Zhong Liu Za Zhi; 2021 May; 43(5):511-515. PubMed ID: 34034468
[TBL] [Abstract] [Full Text] [Related]
[Next]
